Enable JavaScript to visit this website.

Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve.

Click here to learn how we are responding.

Skip to main content
Back to top

Important Safety Information

IMPORTANT SAFETY INFORMATION AND INDICATION
Adverse Reactions
In studies in patients with ATTR-CM, the frequency of adverse events in patients treated with VYNDAQEL® (tafamidis meglumine) was similar to placebo.
Specific Populations
Pregnancy: Based on findings from animal studies, VYNDAQEL and VYNDAMAX may cause fetal harm when administered to a pregnant woman.
Lactation: There are no available data on the presence of tafamidis in human milk, the effect on the breastfed infant, or the effect on milk production. Tafamidis is present in rat milk. When a drug is present in animal milk, it is likely the drug will be present in human milk. Breastfeeding is not recommended during treatment with VYNDAQEL and VYNDAMAX.
Indication
VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
Please see Full Prescribing Information including Patient Information.
VYNDAMAX® AND VYNDAQEL® are registered 
trademarks of Pfizer Inc.
Pfizer Home
  • VYNDAMAX Home

Clinical Information

  • About ATTR-CM
  • Study Design
  • Efficacy and Safety Profile
  • Dosing
  • MOD/MOA

Support & Services

  • Access and Patient Support

Main menu

  • Pfizer Products
  • Support & Services

User menu

  • Sign In
  • Register

This site is intended for U.S. health care professionals.

VYNDAMAX is indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular (CV) mortality and cardiovascular-related hospitalization.
VYNDAMAX is indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular (CV) mortality and cardiovascular-related hospitalization.
  • Indication
  • Important Safety Information
  • Patient Site
  • Full Prescribing Information including Patient Information
EFFICACY AND SAFETY PROFILE
DOSING
STUDY DESIGN

VYNDAMAX is proven to
reduce all-cause mortality and
CV-related hospitalization

LEARN MORE
MOA
A selective stabilizer of TTR
LEARN MORE
ACCESS
VyndaLinkTM connects patients with support
LEARN MORE
IDENTIFY ATTR-CM
Red flags and early diagnosis
LEARN MORE
Back to top

 

NEXT: ABOUT ATTR-CM >

 

Important Safety Information

IMPORTANT SAFETY INFORMATION AND INDICATION
Adverse Reactions
In studies in patients with ATTR-CM, the frequency of adverse events in patients treated with VYNDAQEL® (tafamidis meglumine) was similar to placebo.
Specific Populations
Pregnancy: Based on findings from animal studies, VYNDAQEL and VYNDAMAX may cause fetal harm when administered to a pregnant woman.
Lactation: There are no available data on the presence of tafamidis in human milk, the effect on the breastfed infant, or the effect on milk production. Tafamidis is present in rat milk. When a drug is present in animal milk, it is likely the drug will be present in human milk. Breastfeeding is not recommended during treatment with VYNDAQEL and VYNDAMAX.
Indication
VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
Please see Full Prescribing Information including Patient Information.
VYNDAMAX® AND VYNDAQEL® are registered 
trademarks of Pfizer Inc.

To report an adverse event, please call 1-800-438-1985

Footer logo

Footer links

  • Report Adverse Events
  • Terms of Use
  • Cookies & Privacy Policy
  • Contact
  • Pfizer.com
  • Patient Assistance

Copyright footer block

Pfizer for Professionals 1-800-505-4426

The product information provided in this site is intended only for healthcare professionals in the United States.
The products discussed may have different product labeling in other countries.

© 2021 Pfizer Inc. All Rights Reserved.

PP-VDM-USA-0271